Ex, what would it mean if the 8 patients/30% of the direct trial are still alive? Could that account for the unaffiliated institutional investor(s) demanding so many warrants at such high pps?
"Yes, that trial (AMGEN) continued on blinded after top line data. This would be like NWBO releasing top line PFS data and maintaining the trial blind as they wait on OS." -- exwannabe
You must realize then that NWBO stated this:
"The Company remains blinded to all Trial data, and is only receiving and reporting updates on a blinded basis."
Amgen received and shared data on a blinded basis. Still, they received and shared topline data and maintained the trial blind thereafter.